These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2929747)

  • 41. The dexamethasone suppression test in prepubertal depressed children.
    Weller EB; Weller RA; Fristad MA; Preskorn SH; Teare M
    J Clin Psychiatry; 1985 Dec; 46(12):511-3. PubMed ID: 4066616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic risk for psychosis.
    Collip D; Nicolson NA; Lardinois M; Lataster T; van Os J; Myin-Germeys I;
    Psychol Med; 2011 Nov; 41(11):2305-15. PubMed ID: 21733219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Endocrinologic testing of alcoholics with depressive states--with special reference to the dexamethasone suppression test].
    Suwa K; Takano K; Nishijima K; Ishiguro T; Enomoto M
    Seishin Shinkeigaku Zasshi; 1983; 85(11):823-6. PubMed ID: 6677920
    [No Abstract]   [Full Text] [Related]  

  • 44. Major depressive episode and low dose dexamethasone suppression test.
    Sarai M; Taniguchi N; Kagomoto T; Kameda H; Uema T; Hishikawa Y
    Folia Psychiatr Neurol Jpn; 1982; 36(2):109-14. PubMed ID: 7129257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasma MHPG in depressive disorders and relationship to the dexamethasone suppression test.
    Roy A; Jimerson DC; Pickar D
    Am J Psychiatry; 1986 Jul; 143(7):846-51. PubMed ID: 3717423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The significance of HPA axis disturbance in panic disorder.
    Coryell W; Noyes R; Schlechte J
    Biol Psychiatry; 1989 Apr; 25(8):989-1002. PubMed ID: 2720018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A further exploration of the relationships between immune parameters and the HPA-axis activity in depressed patients.
    Maes M; Bosmans E; Suy E; Minner B; Raus J
    Psychol Med; 1991 May; 21(2):313-20. PubMed ID: 1876636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dexamethasone suppression test as a prognostic tool: two case reports.
    Amsterdam JD; Winokur A; Caroff S
    Am J Psychiatry; 1981 Jul; 138(7):979-80. PubMed ID: 7258362
    [No Abstract]   [Full Text] [Related]  

  • 49. The metyrapone test in schizophrenic patients and healthy subjects.
    Morphy MA; Fava GA; Carson SW; Perini GI; Molnar G; Jusko WJ
    Neuropsychobiology; 1985; 14(1):35-8. PubMed ID: 4069347
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stress hormones and verbal memory in young people over the first 12 weeks of treatment for psychosis.
    Allott KA; Yuen HP; Bartholomeusz CF; Rapado-Castro M; Phassouliotis C; Butselaar F; Wood SJ; Proffitt TM; Savage G; Phillips LJ; Bendall S; Markulev C; Reniers RLEP; Pantelis C; Baldwin L; McGorry PD; Garner B
    Psychiatry Res; 2018 Feb; 260():60-66. PubMed ID: 29175500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of treatment on plasma cortisol and dexamethasone.
    Carson SW; Halbreich U
    Biol Psychiatry; 1987 Feb; 22(2):213-6. PubMed ID: 3814671
    [No Abstract]   [Full Text] [Related]  

  • 52. Longitudinal changes in cortisol secretion and conversion to psychosis in at-risk youth.
    Walker EF; Brennan PA; Esterberg M; Brasfield J; Pearce B; Compton MT
    J Abnorm Psychol; 2010 May; 119(2):401-8. PubMed ID: 20455612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline neuroendocrine function and diagnostic stability among patients with a nonmanic psychosis.
    Coryell W; Zimmermann M; Winokur G; Cadoret R
    Eur Arch Psychiatry Neurol Sci; 1988; 237(4):197-9. PubMed ID: 3203699
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dexamethasone suppression test in autistic children.
    Hoshino Y; Ohno Y; Murata S; Yokoyama F; Kaneko M; Kumashiro H
    Folia Psychiatr Neurol Jpn; 1984; 38(4):445-9. PubMed ID: 6535745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dexamethasone suppression test in positive and negative schizophrenia.
    Altamura C; Guercetti G; Percudani M
    Psychiatry Res; 1989 Oct; 30(1):69-75. PubMed ID: 2594873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated baseline and postdexamethasone cortisol levels. A reflection of severity or endogeneity?
    Whiteford HA; Peabody CA; Csernansky JG; Warner MD; Berger PA
    J Affect Disord; 1987; 12(3):199-202. PubMed ID: 2956304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unhealthy lifestyle in early psychoses: the role of life stress and the hypothalamic-pituitary-adrenal axis.
    Manzanares N; Monseny R; Ortega L; Montalvo I; Franch J; Gutiérrez-Zotes A; Reynolds RM; Walker BR; Vilella E; Labad J
    Psychoneuroendocrinology; 2014 Jan; 39():1-10. PubMed ID: 24274999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Weight change and the dexamethasone suppression test.
    Krishnan KR; France RD; Snipes MT; Pelton S
    Biol Psychiatry; 1985 Sep; 20(9):1018-22. PubMed ID: 4027311
    [No Abstract]   [Full Text] [Related]  

  • 59. Dexamethasone suppression test in schizophrenic patients: report from India.
    Joseph S; Kulhara P; Dash RJ
    Biol Psychiatry; 1987 Jun; 22(6):792-5. PubMed ID: 3593821
    [No Abstract]   [Full Text] [Related]  

  • 60. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression.
    Rothschild AJ; Samson JA; Bond TC; Luciana MM; Schildkraut JJ; Schatzberg AF
    Biol Psychiatry; 1993 Sep; 34(6):392-400. PubMed ID: 8218607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.